{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:28:17Z","timestamp":1785403697633,"version":"3.56.0"},"reference-count":32,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>In older adults with type 2 diabetes (T2DM), tight glycaemic control (HbA1c &lt; 7%) can result in more harm than benefit, especially when using insulin or sulfonylureas. Older adults are at higher risk for adverse drug events, especially hypoglycaemia, which may cause falls, confusion and hospitalisations. This Therapeutic Letter evaluates the risks of tight glycaemic control in older adults with T2DM, focusing on deprescribing diabetes medications in those over 65, especially those with multimorbidity and polypharmacy. It assesses the evidence from clinical trials and guidelines, with a focus on preventing hypoglycaemia and improving patient-centred care through relaxed HbA1c targets. Large randomised controlled trials show that intensive glycaemic control (HbA1c \u2264 7%) does not reduce cardiovascular risk, but increases hypoglycaemia and mortality, particularly in older adults. Instead, glycaemic targets should be adjusted based on the patient\u2019s overall health and life expectancy. Deprescribing may be considered, starting with drugs most likely to cause hypoglycaemia (sulfonylureas or insulin). Regular reassessment and patient involvement in creating individualised treatment plans are essential.<\/jats:p>","DOI":"10.4102\/phcfm.v16i1.4857","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:50:16Z","timestamp":1734637816000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimising harms of tight glycaemic control in older patients with type 2 diabetes"],"prefix":"10.4102","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-4092","authenticated-orcid":false,"given":"Wade","family":"Thompson","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref0","unstructured":"Boyko EJ, Magliano DJ, Karuranga S, et al., editors. International diabetes federation diabetes atlas [homepage on the Internet]. 10th ed. 2021 [cited 2024 Dec 03]. Available from: https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217\u2013230. https:\/\/doi.org\/10.1111\/j.1472-8206.2007.00473.x","DOI":"10.1111\/j.1472-8206.2007.00473.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Lee AK, Juraschek SP, Windham BG, et al. Severe hypoglycemia and risk of falls in type 2 diabetes: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2020;43(9):2060\u20132065. https:\/\/doi.org\/10.2337\/dc20-0316","DOI":"10.2337\/dc20-0316"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Lega IC, Campitelli MA, Austin PC, et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: A population-based study. Diabetologia. 2021;64(5):1093\u20131102. https:\/\/doi.org\/10.1007\/s00125-020-05370-7","DOI":"10.1007\/s00125-020-05370-7"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Abdelhafiz AH, Rodr\u00edguez-Ma\u00f1as L, Morley JE, Sinclair AJ. Hypoglycemia in older people \u2013 A less well recognized risk factor for frailty. Aging Dis. 2015;6(2):156\u2013167. https:\/\/doi.org\/10.14336\/AD.2014.0330","DOI":"10.14336\/AD.2014.0330"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"McCormack JP, Holmes DT. Your results may vary: The imprecision of medical measurements. BMJ. 2020;368:m149. https:\/\/doi.org\/10.1136\/bmj.m149","DOI":"10.1136\/bmj.m149"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","DOI":"10.1056\/NEJMoa0802987"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","DOI":"10.1056\/NEJMoa0802743"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa0808431","DOI":"10.1056\/NEJMoa0808431"},{"key":"ref9","unstructured":"Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes [serial online]. 2018 [cited 2024 Dec 06]; 42 (Suppl. 1):A1\u2013A18, S1\u2013S326. Available from: https:\/\/www.sciencedirect.com\/journal\/canadian-journal-of-diabetes\/vol\/42\/suppl\/S1"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 13. Older adults: Standards of medical care in diabetes \u2013 2022. Diabetes Care. 2022;45(Suppl. 1):S195\u2013S207. https:\/\/doi.org\/10.2337\/dc22-S013","DOI":"10.2337\/dc22-S013"},{"key":"ref11","unstructured":"Society for Endocrinology, Metabolism, and Diabetes of South Africa. Type 2 diabetes guideline committee. In: Glycaemic targets [homepage on the Internet]. 2017 [cited 2024 Dec 03]. Available from: https:\/\/www.semdsa.org.za"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","DOI":"10.1056\/NEJMoa1603827"},{"key":"ref14","unstructured":"Therapeutics Initiative. Pill splitting: Making the most of meds in a time of need [homepage on the Internet]. Therapeutics Letter. Special Edition: March 2020. [cited 2024 Dec 06]. Available from: https:\/\/ti.ubc.ca\/special-edition"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","DOI":"10.1056\/NEJMoa1911303"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","DOI":"10.1056\/NEJMoa1901118"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737. https:\/\/doi.org\/10.1016\/j.diabres.2021.108737","DOI":"10.1016\/j.diabres.2021.108737"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial. Age Ageing. 2019;48(6):859\u2013866. https:\/\/doi.org\/10.1093\/ageing\/afz096","DOI":"10.1093\/ageing\/afz096"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Cahn A, Mosenzon O, Wiviott SD, et al. Efficacy and safety of Dapagliflozin in the elderly: Analysis from the DECLARE\u2013TIMI 58 study. Diabetes Care. 2020;43(2):468\u2013475. https:\/\/doi.org\/10.2337\/dc19-1476","DOI":"10.2337\/dc19-1476"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51(10):afac201. https:\/\/doi.org\/10.1093\/ageing\/afac201","DOI":"10.1093\/ageing\/afac201"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Raghavan S, Matlock D. Diabetes mellitus treatment deintensification: When well-controlled diabetes mellitus becomes overcontrolled. Circ Cardiovasc Qual Outcomes. 2017;10(4):e003706. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.003706","DOI":"10.1161\/CIRCOUTCOMES.117.003706"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Deng Z, Thompson W, Korenvain C, et al. Benefits and harms of deprescribing antihyperglycemics for adults with type 2 diabetes: A systematic review. Can J Diabetes. 2022;46(5):473\u2013479. https:\/\/doi.org\/10.1016\/j.jcjd.2022.01.009","DOI":"10.1016\/j.jcjd.2022.01.009"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Seidu S, Kunutsor SK, Topsever P, et al. Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes. Diabetes Obes Metab. 2019;21(7):1668\u20131679. https:\/\/doi.org\/10.1111\/dom.13724","DOI":"10.1111\/dom.13724"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Oktora MP, Kerr KP, Hak E, Denig P. Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review. Diabetic Med. 2021;38(2):e14408. https:\/\/doi.org\/10.1111\/dme.14408","DOI":"10.1111\/dme.14408"},{"key":"ref26","unstructured":"Farrell B, Black C, Thompson W, et al. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician [serial online]. 2017;63(11):832\u2013843. [cited 2024 Dec 06]. Available from: https:\/\/www.cfp.ca\/content\/63\/11\/832"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: A systematic review. Drugs Aging. 2013;30(10):793\u2013807. https:\/\/doi.org\/10.1007\/s40266-013-0106-8","DOI":"10.1007\/s40266-013-0106-8"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Pilla SJ, Jalalzai R, Tang O, et al. A national survey of physicians\u2019 views on the importance and implementation of deintensifying diabetes medications. J Gen Intern Med. 2024;39(6):992\u20131001. https:\/\/doi.org\/10.1007\/s11606-023-08506-8","DOI":"10.1007\/s11606-023-08506-8"},{"key":"ref29","unstructured":"Farrell B, Mangin D. Deprescribing is an essential part of good prescribing. Am Fam Physician [serial online]. 2019;99(1):7\u20139. [cited 2024 Dec 06]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30600973"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Green AR, Aschmann H, Boyd CM, Schoenborn N. Assessment of patient-preferred language to achieve goal-aligned deprescribing in older adults. JAMA Netw Open. 2021;4(4):e212633. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.2633","DOI":"10.1001\/jamanetworkopen.2021.2633"},{"key":"ref31","unstructured":"The Therapeutics Initiative. Therapeutics Letter. Vancouver, BC: Therapeutics Initiative, Letter 151, Minimizing harms of tight glycemic control in older people with type 2 diabetes; 2024."}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"link":[{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4857\/7826","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4857\/7827","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4857\/7828","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4857\/7829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/4857\/7829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:41:46Z","timestamp":1777034506000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/4857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,21]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v16i1.4857","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"a4857"}}